A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Principal Investigator

Elie Traer

Study Purpose

The main purpose of this study is to test the safety of a study drug called IMGN779. This study will test different doses and dosing schedules of the drug to see which dose is safer in people and to find out what effects, if any, it has on people with Acute Myeloid Leukemia (AML)

Medical Condition(s)

Relapsed/Refractory AML

Eligibility Criteria

You may be eligible if you:
-Have AML and, after treatment, your disease has either relapsed (come back) or is refractory (has not responded to treatment)
-Are at least 18 years old
-Have blood cells positive for a certain protein (CD33)

Age Range

18 - none

Healthy Volunteers Needed


Duration of Participation

You will receive the study drug for as long as you are tolerating it and your leukemia has not gotten worse. After you finish receiving the study drug, the investigator will continue to watch you for side effects and follow your condition 30 days after your last dose of study drug and then every 3 months until your disease progresses, you begin an anti-cancer treatment, or you withdraw consent.

Minors Included



Clinical Trials Information Line
Phone: 503-494-1080


ImmunoGen, Inc.

Recruitment End


Compensation Provided


Go Back